动物模型在精神与物质使用障碍治疗开发中的有效运用
本文主张采用「转化-反向转化策略」进行中枢神经系统药物发现,即在人类概念验证研究中先使用已确立安全性的药物,再平行开展实验动物研究以揭示神经机制。综述列举了注意缺陷多动障碍认知缺陷治疗、基于低剂量氯胺酮快速起效抗抑郁药开发及物质滥用新药三个示例,并呼吁建立学术-产业联盟开放共享数据。
要点
- 主张转化-反向转化策略:先在人体验证安全性已知药物,再平行开展动物实验揭示神经机制。
- 列举注意缺陷多动障碍认知缺陷、低剂量氯胺酮快速抗抑郁及物质滥用治疗三个开发示例。
- 呼吁建立学术-产业联盟,开放共享临床前与临床数据以加速精神疾病新药研发。
核心结论
- 采用转化-反向转化策略可有效推进精神与物质使用障碍的治疗开发。
- 临床与临床前研究的双向信息交换有助于加速新药发现。
研究设计与样本
- 本文为综述,未报告系统检索范围或样本量。
主要发现
- 低剂量氯胺酮在临床中显示出有前景的快速抗抑郁效应。
- 已确立安全性的药物可用于人类概念验证研究并指导平行动物实验。
临床怎么用
- 可优先评估安全性已知药物在人体中的概念验证效果,再平行开展动物实验阐明神经机制。
- 推动学术与产业联盟合作,开放共享临床前与临床数据以支持药物开发。
局限性
- 原文未报告综述的检索策略、纳入标准或证据质量评价。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Athina Markou and others argue forcefully for the adoption of a "translational-back translational strategy" for central nervous system drug discovery involving novel application of drugs with established safety profiles in proof-of-principle studies in humans, which in turn encourage parallel studies using experimental animals to provide vital data on the neural systems and neuropharmacological mechanisms related to the actions of the candidate drugs. Encouraged by the increasing adoption of drug-development strategies involving reciprocal information exchange between preclinical animal studies and related clinical research programs, this review presents additional compelling examples related to the following: 1) the treatment of cognitive deficits that define attention-deficit/hyperactivity disorder; 2) the development of fast-acting antidepressants based on promising clinical effects with low doses of the anesthetic ketamine; and 3) new and effective medications for the treatment of substance misuse. In the context of addressing the unmet medical need for new and effective drugs for treatment of mental ill health, now may be the time to launch major new academic-industry consortia committed to open access of all preclinical and clinical data generated by this research.
引用
- Phillips AG, Geyer MA, Robbins TW, et al. Effective Use of Animal Models for Therapeutic Development in Psychiatric and Substance Use Disorders. Biol Psychiatry. 2018. PMID: 29478700. doi:10.1016/j.biopsych.2018.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。